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A Total Solution for Maximising Antibody Response
DNA vaccination leads to intracellular production of proteins, which are endogenous anti-
gen in nature. It favours the specific type of immune response, which IS mediated by the
r--lajol- Histocompatibility Complex (MHC) class I pathway, resulting a strong antiqen-
specific cytotoxic T lymphocytes (CTl) response. In contrast, the protein vacc.nanon IS
bias towards the MHC class II pathway and the antigens encountered are exogenous.
CD8+ cytotoxic T cells are more effective in eliminating vir-uses that are protected by the cell they reside
in. T cells do not neutralize virus particles or viral antigens that are present outside of the cells. Antibodies
produced by tile host bind and form a complex with extracellular viruses or antigens. If virus par-ticles al-e
the target antigens, the antigen-antibody binding will lead to the neutralizat.on of INUS from infecting host
cells. Therefore, antibodies are important in eliminating infectious viruses or antigens frorn infectmq host
cells. However, the level of antibodies generated following vaccination With DNA vaccines IS relatively low.
Several Approaches have been taken to further improve the humoral response of DNA vaccines without
suppressing the T cell (CTl) response. For instance, improvement of plasmid backbone and injection vehi-
cles to increase expression of antioen in muscle, co-rnjecuon with plasmid encoding co-stimulating mole-
cules, cvtoktnes or chemokines (Pasquini et al. 1997;
Kim and Weiner, 1997), and the lise of plasmid DNA
encoding fusion proteins to facilitate antigen tar qetrno
or influence antigen IDealization (Planelles et al.
2001 ).
In the resear-ch conducted, the concept of fusion gene
is employed to tmprove antigen processing and pres-
entation. Nucleopmtein (NP) gene (from viruses of
family Orthomyxoviriclae or- Paramyxovlridae) IS cho-
sen because NP DNA vaccines has successfully m-
duced strono CTl responses and at the same time
producing Cl high level of antigen specific antibodies,
mainly [gG2a subclass via cross priming (Yankauckas
et al. 1993) It is used as an immunoenilancer and
can assure that an mcrease In the level of ant.body production does not suppress the development of CTL
(II111
Positive immunoperoxidase staining of rat oocytes by
antisera raised to (A) IMURONTM-ZP3 (B) empty
IMURONTM, as negative control (C) rec-ZP3 as
positive control, collected I month after the first
injection. Antisera used were at Q dilution of 1:50.
responses. Unlike cytokine genes, enhancement or antibody immune response IS sometimes accornpan.eo
by a suppression of ceil-mediated immune response and also Inhibition in the expression of immune memory
response following Cle1ministr"'ation of [LA.
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ZP3 (zona pellucida 3) DNA vaccine is a good example. Antibody against ZP3 protein was too low to be
detected by ELISA despite of three intramuscular injections (booster doses) with ZP3 DNA vaccine (SO-
lDO iJg/animal). As most of the DNA vaccines, ZP3 vaccine has preference towards cell-mediated immune
response. When ZP3 protein is genetically conjugated with NP protein, production of antibodies against
ZP3 protein has increased substantially up to more than 100 folds.
The NPgene was cloned into pcDNA3 using HindIII and feaRI sites to yield IMURONn,.The IMURON'" was
designed to express NP conjugated protein. The termination codon of NP gene was replaced with HIS6
coding sequence and limited number of enzyme restriction sites via peR. HIS-tag functions as reporter
gene while the enzyme restriction sites facilitate cloning of second gene, the gene of interest.
To test the efficacy of IMURONn." the 5' terminus of ZP3 gene was ligated to the 3' terminus of the NP
DNA sequence at fcaR! restriction site. The resultant recombinant was denoted as !MURONTr·'-ZP3.
IMURON™is a patent pending PI20023353 invention.
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